Fourth, previous ENGAGE AF‐TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation‐Thrombolysis in Myocardial Infarction Study 48) studies have demonstrated population differences in edoxaban response between Asian and non‐Asian populations [27, 28]. This evidence concerns the gene F10 and atrial fibrillation.